Oncotelic Therapeutics Highlighted in BioMedWire Editorial on CNS Drug Delivery Innovation
Oncotelic Therapeutics was featured in a BioMedWire editorial examining breakthroughs in central nervous system drug delivery, highlighting its proprietary intranasal nose-to-brain delivery platform that aims to overcome the blood-brain barrier for neurological diseases and biodefense applications.
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has been featured in a BioMedWire editorial that explores emerging breakthroughs in central nervous system drug delivery and the growing market opportunities tied to overcoming the blood-brain barrier. The editorial, which examines the challenges and innovations in CNS therapeutics, positions Oncotelic within a broader industry effort to advance next-generation treatments for neurological disease, biodefense applications, and other CNS-related conditions.
According to the press release, the editorial highlights Oncotelic’s proprietary intranasal nose-to-brain delivery platform, designed to enable rapid, targeted therapeutic access to the brain. This technology could address one of the most significant hurdles in CNS drug development: the blood-brain barrier, which prevents many potential treatments from reaching their targets. The platform’s ability to deliver drugs directly to the brain via the nasal route offers a non-invasive alternative to traditional methods, potentially improving patient outcomes and expanding treatment options for conditions such as brain tumors, neurodegenerative diseases, and biodefense threats.
The editorial underscores the importance of this innovation as the demand for effective CNS therapies grows. With an aging global population and increasing prevalence of neurological disorders, the market for CNS drugs is projected to expand significantly. Oncotelic’s delivery platform could capture a share of this market by enabling existing and new therapies to cross the blood-brain barrier more effectively.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, addressing high-unmet-need cancers and rare pediatric indications. The company benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. Additionally, Oncotelic leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration.
Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures. The company owns a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates that further strengthens its position in oncology and rare disease therapeutics.
The full press release is available at https://ibn.fm/Y8E3U. For more information about Oncotelic, visit their newsroom at https://ibn.fm/OTLC.